Navigation Links
Mount Sinai researchers to present studies at American Society of Clinical Oncology Meeting
Date:5/31/2014

(New York UNDER EMBARGO May 31, 2014) Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2014 American Society of Clinical Oncology (ASCO) meeting May 30-June 3, 2014 in Chicago, including data on new treatment approaches for thyroid, head and neck, and recurrent ovarian cancers; and new biomarkers for bile duct cancers.

Highlights of Mount Sinai research at ASCO:

  • Phase II Trial on the Combination of Bevacizumab and Irinotecan in Recurrent Ovarian Cancer (Under Embargo Until SATURDAY, MAY 31, 8:00 11:45 AM)

    In a study led by Amy Tiersten, MD, Associate Professor in the Division of Hematology and Medical Oncology and a member of the Breast Cancer Medical Oncology Program, Icahn School of Medicine at Mount Sinai, the efficacy and safety of Bevacizumab and Irinotecan in patients with recurrent ovarian cancer was observed. Researchers sought to determine how well this combination worked during and after 6 months of treatment, and to estimate the length of time the cancer did not get worse. Secondary objectives were to discover overall survival, observed response rate, duration of response, and toxicity. Of the 24 patients continuing in the study, 8 experienced a partial response, 13 remained stable with no progression of the disease and 3 progressed in their disease. The observed response rate was 27.6%, and the clinical benefit rate was 72.4%. Twelve patients had longer than 6 months of sustained response, and the median disease progression free response rate was 8.1 months. Adverse events were within the known side effects, with the most common being diarrhea, and no treatment-related deaths were observed.

    "Our findings give hope to women with recurrent, advanced-stage ovarian cancer. The combination showed encouraging results in heavily-pretreated patients with this recurrent disease," said Dr. Tiersten. "This trial proves the effectiveness of this combination, and provi
    '/>"/>


Contact: Lucia Lee
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Mount Sinai researchers lead committee to define the clinical course of multiple sclerosis
2. Mount Sinai presents important findings at the 2014 American Urological Association Meeting
3. Mount Sinai researchers identify changes that may occur in neural circuits due to addiction
4. The power of protein at breakfast; higher amounts may deliver more benefits
5. Mount Sinai researchers find promising new drug targets for cocaine addiction
6. As Lipitor Lawsuits Mount, Bernstein Liebhard LLP Notes Publication of New Study with Possible Explanation for Link between Statins and Diabetes
7. Mount Sinai Queens Names New Orthopaedics Dept. Chief
8. Da Vinci Robot Lawsuits Mount, as Bernstein Liebhard LLP Comments on AARP Robotic Surgery Concerns
9. Bernstein Liebhard LLP Launches New Transvaginal Mesh Lawsuit Website as Claims Continue to Mount in U.S. Litigations
10. Pradaxa Lawsuits Mount, as Claims in Federal Multidistrict Litigation Exceed 2,000, Bernstein Liebhard LLP Reports
11. 2014 GoPro Mountain Games Evolves the Family Friendly Mud Run and Adds BADASS Dash Obstacle Course Race to Competition Line-Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 02, 2015 Formetco today announced the ... The FTX uses state-of-the-art technology to deliver an ... and owner satisfaction. An item of particular value, ... Formetco 10 year LED Brightness Warranty. , Why the ... a superior billboard among any other billboard product in ...
(Date:3/2/2015)... 02, 2015 Calvary Hospital recently ... Brooklyn Satellite in Lutheran Medical Center, with the ... must demonstrate excellence through clinical expertise as well ... to go above and beyond to make a ... patients and their families. Award recipients are chosen ...
(Date:3/2/2015)... Getting customers to discover a whole ... this March as the 31st annual Frozen Food Month ... Frozen & Refrigerated Foods Association (NFRA) to stimulate the ... than 20 delicious frozen selections and is thrilled to ... frozen options are crafted with simple ingredients, no preservatives ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Today ... Luis Obispo), in partnership with the California Healthcare ... Disorders (NORD), presented an Assembly resolution recognizing Feb. ... families and healthcare professionals caring for millions of ... is a nonprofit, public policy research organization, representing ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... behalf of women who were allegedly harmed by the ... state and federal courts around the U.S., according to ... U.S. District Court, Eastern District of California on February ... a case pending in that jurisdiction may pursue her ...
Breaking Medicine News(10 mins):Health News:Formetco Launches Innovative LED Billboard System 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 2Health News:California Healthcare Institute Spotlights Impact of Rare Diseases with Assemblymember Katcho Achadjian 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 4
... Cost Saving Benefit Faces Eventual Elimination Without Relief ... support of President Obama,s pledge not to raise taxes on ... -- outside of the normal legislative process -- adopting provisions ... restrict the use of flexible spending accounts (FSAs) in order ...
... Oct. 14 New Enterprise Associates, Inc. (NEA), a leading ... has been promoted to General Partner. Dr. Viswanathan, who joined ... equity information technology investments, as well as the firm,s activities ... Principal. Dr. Torti joined NEA in 2007 and is focused ...
... Networks , the nation,s leading provider of physician office-based ... consumer purchase behavior, not just purchase intent, for OTC ... revenue and justify investments designed to capture market share, ... health messages to purchase volume. To address this need ...
... aged 70-79, the apparent association between light-to-moderate alcohol consumption ... not hold up after adjustments were made for characteristics ... education, and income. The authors of the ... American Geriatrics Society , say this suggests that life-style ...
... SAN DIEGO, Oct. 14 Cardium Therapeutics (NYSE Amex: ... Matrix Phase 2b clinical trial of Excellarate(TM) for the ... ulcers based on the Company,s Gene Activated Matrix (GAM) ... the Excellarate product candidate (GAM501, which is a combination ...
... Continuing its efforts to educate, inform, and empower ... patient-focused organization, is hosting its 25-minute live call-in show, ... Monday, October 19, 2009 at 6:00 PM on Channel ... frank discussion regarding Retail Health Clinics with Erin Buckley, ...
Cached Medicine News:Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 2Health News:Fight to Preserve Flexible Spending Accounts Moves to the House of Representatives 3Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 2Health News:Healthy Advice Networks Now Able to Track Consumer Purchase Behavior 3Health News:'Beneficial' effects of alcohol? 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 2Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 3Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 4Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 5Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 6Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 7Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 8Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 9Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 10Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 11Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 12Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 13Health News:Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program 14Health News:Retail Health Clinics - The Real Story 2
(Date:3/2/2015)... March 2, 2015 Cure SMA recently announced a ... Biomedical Research (CALIBR). This funding is an extension of a ... a $700,000 Cure SMA grant to Dr. Peter G. ... "Optimization of Small Molecules that Increase SMN2 Levels ... motor neuron (SMN) protein is critical to the function of ...
(Date:3/2/2015)...  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... for the fiscal first quarter 2015 after the market ... The Company will also host a conference call for ... Central Time (10:00 a.m. Eastern Time). Investors may access ...
(Date:3/2/2015)... 2015 Amgen (NASDAQ: AMGN ) ... data evaluating Repatha TM (evolocumab), an investigational cholesterol-lowering ... for chronic heart failure, at the upcoming American College ... being held March 14-16 in San Diego ... monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 ...
Breaking Medicine Technology:Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11
... in Poor Risk Frontline Elderly AML and in Combination with Cytarabine ... Call Scheduled for Tuesday, December 9 at 11:00 am ET to ... , SAN FRANCISCO , Dec. 7 ... the presentation of new data from two ongoing clinical trials demonstrating ...
... carisbamate, an,investigational compound recently filed with the FDA for ... 16 years of age and,older, was presented today during ... American Epilepsy Society. , ... efficacy, safety and tolerability of carisbamate as an,adjunctive treatment ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 2Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 3Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 4Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 5
... 4420 Colloid Osmometer. Rapid measurement of ... prediction of edema onset in clinical ... sample and reference chambers to simulate ... membrane in the establishment of osmotic ...
... Automated Cortisol assay with flexible ... workflow, Excellent correlation and agreement ... confidence,in assay performance, Standardized to ... Panels delivers assurance in,accuracy of ...
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
Medicine Products: